PRESTIGE BIOPHARMA LIMITED

Prestige Biopharma is one of the fastest growing biopharmaceuticals focusing on the development of biosimilars and first-in-class antibody drugs as well as vaccines for infectious diseases. With decades of R&D and operational experience in drug discovery, we expedite future biologics development and commercialization in a concerted approach based on our proprietary technologies and scientific capabilities. Prestige strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-Ulenistamab) that recently obtained orphan designation from FDA, EMA and MFDS. Prestige’s rich portfolio of biosimilars in various stages including HD201 trastuzumab in EU EMA’s MAA review, HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. Prestige has expanded its business into development and manufacturing of vaccines through its global scale vaccine center, starting with partnered commercial production of COVID-19 vaccines.

Prestige Biopharma 是增长最快的生物制药公司之一，专注于开发生物类似药、首创抗体药物以及传染病疫苗。凭借数十年的药物发现研发和运营经验，我们利用专有技术和科学能力，以协调一致的方式加速未来生物制剂的开发和商业化。Prestige 致力于成为全球创新者，开发首创抗体疗法，包括用于胰腺癌的 PBP1510 抗 PAUF 单克隆抗体（INN-Ulenistamab），该药物最近获得了 FDA、EMA 和 MFDS 的孤儿药资格。Prestige 拥有丰富的生物类似药产品组合，处于不同阶段，包括在欧盟 EMA 的 MAA 审评中的 HD201 曲妥珠单抗、全球 III 期的 HD204 贝伐珠单抗、I 期的 PBP1502 阿达木单抗等，旨在为有需要的人提供可负担的优质药物。Prestige 已通过其全球规模的疫苗中心将业务扩展至疫苗的开发和生产，首先是与合作伙伴进行 COVID-19 疫苗的商业化生产。